RxDoctor Payments Data

Mary Davis, NP

Family · Greenville, SCNPI 1548880743

Payments from drug & device makers

$407in general payments, 2019–2025

Across 20 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$148
  • Boehringer Ingelheim$54
  • Amarin Pharma, Inc.$54
  • Merck$43
  • GSK$38
  • Eisai Inc.$29
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 45th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$29,601
Medicare patients
102
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$109,084
OzempicSemaglutide70$72,396
TradjentaLinagliptin58$53,493
EliquisApixaban52$43,564
RybelsusSemaglutide16$35,821
MounjaroTirzepatide28$32,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,981
XareltoRivaroxaban23$18,132
JanuviaSitagliptin Phosphate19$17,086
TrulicityDulaglutide12$10,945
SymbicortBudesonide/Formoterol Fumarate11$5,772
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,640
Albuterol Sulfate HfaAlbuterol Sulfate186$5,530
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,927
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$3,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$54$162,577157 claims
Novo NordiskOzempic, Rybelsus$148$108,21786 claims
Lilly USA, LLCMounjaro, Trulicity$17$43,75940 claims
GSKTrelegy Ellipta, Anoro Ellipta$38$35,62155 claims
MerckJanuvia$43$17,08619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →